Berenberg raises target for Fresenius stock to EUR 54

Published on 10/26/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached EUR 5.864 billion, up 6.00 percent year over year. Fresenius stock costs EUR 46.13 on October 26, 2026 versus EUR 46.10.

Ownership expands biosimilar platform

Fresenius completed the mAbxience acquisition for up to EUR 750 million on September 30, 2026.
Second-quarter revenue reached EUR 5.864 billion, up 6.00 percent year over year.
Fresenius stock trades at EUR 46.13 at 10:06 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.07 percent above the Xetra close of October 23, 2026.
Berenberg raised its price target from EUR 50 to EUR 54 in its October 22, 2026 study.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) was trading at EUR 46.13 at Lang & Schwarz on October 26, 2026 at 10:06 a.m. CEST, 0.07 percent above the Xetra close of October 23, 2026 (EUR 46.10). MarketScreener reported that Berenberg raised its Fresenius target from EUR 50 to EUR 54 on October 22, 2026 and kept a Buy rating.

Why the target moved higher

Berenberg analyst Harry Gillis said the market still values Fresenius mainly through its hospital business, while the group is shifting toward biosimilars, specialized nutrition and medical technology. The report also put Berenberg's 2027 earnings forecast 2.00 percent above consensus, giving the target change a quantified basis.

The analyst update followed Fresenius' mAbxience transaction. In its release dated October 1, 2026, Fresenius said it had acquired the remaining 45 percent of mAbxience for total consideration of up to EUR 750 million. The transaction was signed and completed on September 30, 2026, and the company said it should immediately add to core earnings per share.

Three dates shape the story

On August 5, 2026, Fresenius reported second-quarter revenue of EUR 5.864 billion, up 6.00 percent year over year, while group EBIT rose 10.00 percent to EUR 719 million, according to the company's investor-relations page. On September 30, 2026, Fresenius completed the mAbxience acquisition for up to EUR 750 million.

On October 22, 2026, Berenberg raised its target from EUR 50 to EUR 54. This chronology points to a consistent investment case: operating figures, portfolio ownership and analyst valuation all center on the company's higher-growth Kabi businesses.

What date comes next

Fresenius will publish its third-quarter 2026 results on November 4, 2026, with the conference call scheduled for 1:30 p.m. CET, according to the company's financial-results page. That report will provide the next test of the raised full-year core earnings outlook.

Stock holds above the Xetra close

The euro quotation is only 0.07 percent above the Xetra close, so the October 22 target increase is the clearer market context than the small intraday difference. Fresenius had a market capitalization of EUR 26.0 billion as of October 26, 2026, while its 52-week range stood at EUR 35.11 to EUR 52.96.

Fresenius was trading at EUR 46.13 at Lang & Schwarz on October 26, 2026 at 10:06 a.m. CEST, 0.07 percent above the Xetra close of October 23, 2026 (EUR 46.10). The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.